<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Reprod Med Biol</journal-id><journal-id journal-id-type="iso-abbrev">Reprod. Med. Biol</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1447-0578</journal-id><journal-id journal-id-type="publisher-id">RMB2</journal-id><journal-title-group><journal-title>Reproductive Medicine and Biology</journal-title></journal-title-group><issn pub-type="ppub">1445-5781</issn><issn pub-type="epub">1447-0578</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29259450</article-id><article-id pub-id-type="pmc">5715878</article-id><article-id pub-id-type="doi">10.1002/rmb2.12008</article-id><article-id pub-id-type="publisher-id">RMB212008</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Phase <styled-content style="fixed-case">III</styled-content> trial comparing the efficacy and safety of recombinant&#x02010; or urine&#x02010;derived human chorionic gonadotropin for ovulation triggering in Japanese women diagnosed with anovulation or oligo&#x02010;ovulation and undergoing ovulation induction with follitropin&#x02010;alfa</article-title></title-group><contrib-group><contrib id="rmb212008-cr-0001" contrib-type="author" corresp="yes"><name><surname>Ikenaga</surname><given-names>Hideyuki</given-names></name><address><email>incho@bashamichi-lc.net</email></address><xref ref-type="aff" rid="rmb212008-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="rmb212008-cr-0002" contrib-type="author"><name><surname>Tanaka</surname><given-names>Yudai</given-names></name><xref ref-type="aff" rid="rmb212008-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="rmb212008-cr-0003" contrib-type="author"><name><surname>Shiotani</surname><given-names>Masahide</given-names></name><xref ref-type="aff" rid="rmb212008-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="rmb212008-cr-0004" contrib-type="author"><name><surname>Rogoff</surname><given-names>Daniela</given-names></name><xref ref-type="aff" rid="rmb212008-aff-0004">
<sup>4</sup>
</xref><xref ref-type="aff" rid="rmb212008-curr-0001">
<sup>7</sup>
</xref></contrib><contrib id="rmb212008-cr-0005" contrib-type="author"><name><surname>Shimizu</surname><given-names>Shin</given-names></name><xref ref-type="aff" rid="rmb212008-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="rmb212008-cr-0006" contrib-type="author"><name><surname>Ishihara</surname><given-names>Osamu</given-names></name><xref ref-type="aff" rid="rmb212008-aff-0006">
<sup>6</sup>
</xref></contrib></contrib-group><contrib-group><contrib id="rmb212008-cr-0007" contrib-type="author"><name><surname>Sato</surname><given-names>Yoshiaki</given-names></name></contrib><contrib id="rmb212008-cr-0008" contrib-type="author"><name><surname>Morimoto</surname><given-names>Yoshiharu</given-names></name></contrib><contrib id="rmb212008-cr-0009" contrib-type="author"><name><surname>Fukuda</surname><given-names>Aisaku</given-names></name></contrib><contrib id="rmb212008-cr-0010" contrib-type="author"><name><surname>Aisaka</surname><given-names>Kohzo</given-names></name></contrib><contrib id="rmb212008-cr-0011" contrib-type="author"><name><surname>Yoshida</surname><given-names>Koji</given-names></name></contrib><contrib id="rmb212008-cr-0012" contrib-type="author"><name><surname>Hayashi</surname><given-names>Naoki</given-names></name></contrib><contrib id="rmb212008-cr-0013" contrib-type="author"><name><surname>Oku</surname><given-names>Hirotsugu</given-names></name></contrib><contrib id="rmb212008-cr-0014" contrib-type="author"><name><surname>Abe</surname><given-names>Yuji</given-names></name></contrib><contrib id="rmb212008-cr-0015" contrib-type="author"><name><surname>Haruki</surname><given-names>Atsushi</given-names></name></contrib><contrib id="rmb212008-cr-0016" contrib-type="author"><name><surname>Ishikawa</surname><given-names>Motoharu</given-names></name></contrib><contrib id="rmb212008-cr-0017" contrib-type="author"><name><surname>Kuramoto</surname><given-names>Takeshi</given-names></name></contrib></contrib-group><aff id="rmb212008-aff-0001">
<label><sup>1</sup></label>
<institution>Bashamichi Ladies Clinic</institution>
<named-content content-type="city">Yokohama</named-content>
<country country="JP">Japan</country>
</aff><aff id="rmb212008-aff-0002">
<label><sup>2</sup></label>
<institution>Medical Park Shonan</institution>
<named-content content-type="city">Fujisawa</named-content>
<country country="JP">Japan</country>
</aff><aff id="rmb212008-aff-0003">
<label><sup>3</sup></label>
<institution>Hanabusa Women's Central Fertility Clinic</institution>
<named-content content-type="city">Kobe</named-content>
<country country="JP">Japan</country>
</aff><aff id="rmb212008-aff-0004">
<label><sup>4</sup></label>
<institution>EMD Serono Research &#x00026; Development Institute, Inc.</institution>
<named-content content-type="city">Billerica</named-content>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><aff id="rmb212008-aff-0005">
<label><sup>5</sup></label>
<institution>Merck Serono Company, Ltd</institution>
<named-content content-type="city">Tokyo</named-content>
<country country="JP">Japan</country>
</aff><aff id="rmb212008-aff-0006">
<label><sup>6</sup></label>
<institution>Saitama Medical University Hospital</institution>
<named-content content-type="city">Saitama</named-content>
<country country="JP">Japan</country>
</aff><aff id="rmb212008-curr-0001"><label><sup>7</sup></label>Present address:
<institution>Versartis, Inc.</institution>
<named-content content-type="city">Menlo Park</named-content>
<named-content content-type="country-part">CA</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Hideyuki Ikenaga, Bashamichi Ladies Clinic, Naka&#x02010;ku, Yokohama&#x02010;shi, Kanagawa, Japan.<break/>
Email: <email>incho@bashamichi-lc.net</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>04</day><month>12</month><year>2016</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2017</year></pub-date><volume>16</volume><issue>1</issue><issue-id pub-id-type="doi">10.1111/rmb2.2017.16.issue-1</issue-id><fpage>45</fpage><lpage>51</lpage><history><date date-type="received"><day>26</day><month>4</month><year>2016</year></date><date date-type="accepted"><day>29</day><month>6</month><year>2016</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2017 Japan Society for Reproductive Medicine <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2016 The Authors. Reproductive Medicine and Biology published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Japan Society for Reproductive Medicine.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:RMB2-16-45.pdf"/><abstract id="rmb212008-abs-0001"><title>Abstract</title><sec id="rmb212008-sec-0001"><title>Aim</title><p>Outside of Japan, recombinant&#x02010;human chorionic gonadotropin (r&#x02010;<styled-content style="fixed-case">hCG</styled-content>) is widely used for the induction of final follicular maturation and early luteinization in women undergoing ovulation induction; whereas in Japan, urine&#x02010;derived <styled-content style="fixed-case">hCG</styled-content> (u&#x02010;<styled-content style="fixed-case">hCG</styled-content>) is predominantly used. The primary objective of this study was to demonstrate the non&#x02010;inferiority of r&#x02010;<styled-content style="fixed-case">hCG</styled-content> to u&#x02010;<styled-content style="fixed-case">hCG</styled-content> for ovulation induction, as assessed by the ovulation rate.</p></sec><sec id="rmb212008-sec-0002"><title>Methods</title><p>This was an open&#x02010;label, parallel&#x02010;group, randomized, multicenter, phase <styled-content style="fixed-case">III</styled-content> trial in Japanese women with anovulation or oligo&#x02010;ovulation secondary to hypothalamic&#x02013;pituitary dysfunction or polycystic ovary syndrome, undergoing ovulation induction with recombinant&#x02010;human follicle&#x02010;stimulating hormone. The women were randomized (2:1) to receive either a single 250&#x000a0;&#x003bc;g s.c. dose of r&#x02010;<styled-content style="fixed-case">hCG</styled-content> or a single 5000&#x000a0;<styled-content style="fixed-case">IU</styled-content> i.m. dose of u&#x02010;<styled-content style="fixed-case">hCG</styled-content> for ovulation triggering.</p></sec><sec id="rmb212008-sec-0003"><title>Results</title><p>Eighty&#x02010;one women were randomized to either r&#x02010;<styled-content style="fixed-case">hCG</styled-content> (n=54) or u&#x02010;<styled-content style="fixed-case">hCG</styled-content> (n=27).&#x000a0;Ovulation occurred in 100% of the participants and treatment with r&#x02010;<styled-content style="fixed-case">hCG</styled-content> was&#x000a0;observed to be non&#x02010;inferior to u&#x02010;<styled-content style="fixed-case">hCG</styled-content> for ovulation induction. Overall, the type and severity of adverse events were as expected for women receiving fertility treatment.</p></sec><sec id="rmb212008-sec-0004"><title>Conclusion</title><p>This study demonstrated that r&#x02010;<styled-content style="fixed-case">hCG</styled-content> was non&#x02010;inferior to u&#x02010;<styled-content style="fixed-case">hCG</styled-content> for inducing ovulation. Furthermore, r&#x02010;<styled-content style="fixed-case">hCG</styled-content> demonstrated an expected safety profile, with no new safety concerns identified.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="rmb212008-kwd-0001">assisted reproductive techniques</kwd><kwd id="rmb212008-kwd-0002">human chorionic gonadotropin</kwd><kwd id="rmb212008-kwd-0003">oocyte retrieval</kwd><kwd id="rmb212008-kwd-0004">ovulation</kwd><kwd id="rmb212008-kwd-0005">ovulation induction</kwd></kwd-group><funding-group><award-group><funding-source>Merck KGaA, Darmstadt, Germany</funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="3"/><page-count count="7"/><word-count count="4607"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>rmb212008</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.2.7 mode:remove_FC converted:04.12.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="rmb212008-cit-1001">
<string-name>
<surname>Ikenaga</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Shiotani</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Rogoff</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Shimizu</surname>, <given-names>S.</given-names>
</string-name> and <string-name>
<surname>Ishihara</surname>, <given-names>O.</given-names>
</string-name> (<year>2017</year>), <article-title>Phase III trial comparing the efficacy and safety of recombinant&#x02010; or urine&#x02010;derived human chorionic gonadotropin for ovulation triggering in Japanese women diagnosed with anovulation or oligo&#x02010;ovulation and undergoing ovulation induction with follitropin&#x02010;alfa</article-title>. <source>Reproductive Medicine and Biology</source>, <volume>16</volume>: <fpage>45</fpage>&#x02013;<lpage>51</lpage>. doi: <ext-link ext-link-type="doi" xlink:href="10.1002/rmb2.12008">10.1002/rmb2.12008</ext-link>.</mixed-citation>
</p><fn-group id="rmb212008-ntgp-0001"><fn id="rmb212008-note-1001"><p>EMD Serono Research &#x00026; Development Institute, Inc. is a business of Merck KGaA, Darmstadt, Germany.</p></fn><fn id="rmb212008-note-1002"><p>Merck Serono Company, Ltd is an affiliate of Merck KGaA, Darmstadt, Germany.</p></fn></fn-group></notes></front><body><sec id="rmb212008-sec-0005"><label>1</label><title>Introduction</title><p>Human chorionic gonadotropin (hCG) is widely used as a surrogate for luteinizing hormone to induce final oocyte maturation in women who are undergoing ovulation induction.<xref rid="rmb212008-bib-0001" ref-type="ref">1</xref> Globally, both recombinant&#x02010;hCG (r&#x02010;hCG) and urine&#x02010;derived hCG (u&#x02010;hCG) are used for this purpose, with r&#x02010;hCG typically used at a dose of 250&#x000a0;&#x003bc;g and u&#x02010;hCG used at a dose of 5000&#x02013;10&#x000a0;000&#x000a0;IU.<xref rid="rmb212008-bib-0001" ref-type="ref">1</xref> Outside of Japan, comparative clinical trials have demonstrated that administration of 250&#x000a0;&#x003bc;g of r&#x02010;hCG is as effective as 5000&#x000a0;IU and 10&#x000a0;000&#x000a0;IU of u&#x02010;hCG for the induction of final follicular maturation and early luteinization in assisted reproductive techniques and as effective as 5000&#x000a0;IU of u&#x02010;hCG for ovulation induction.<xref rid="rmb212008-bib-0002" ref-type="ref">2</xref>, <xref rid="rmb212008-bib-0003" ref-type="ref">3</xref>, <xref rid="rmb212008-bib-0004" ref-type="ref">4</xref> A meta&#x02010;analysis of nine of these trials observed a mean (95% confidence interval [CI]) difference of &#x02212;0.04 (&#x02212;0.69&#x02010;0.62) oocytes retrieved with r&#x02010;hCG, compared with u&#x02010;hCG, and no statistically significant difference (<italic>P</italic>=.28) between the preparations for the ongoing pregnancy or live birth rates.<xref rid="rmb212008-bib-0005" ref-type="ref">5</xref> However, a lower risk of adverse events (AEs) has been observed with r&#x02010;hCG compared with u&#x02010;hCG (odds ratio [95% CI] 0.39 [0.25&#x02010;0.61]).<xref rid="rmb212008-bib-0005" ref-type="ref">5</xref> These AEs include injection site reactions, such as pain, inflammation, itching, and bruising, which have been observed in clinical trials to occur in fewer women who receive r&#x02010;hCG, compared with those who receive u&#x02010;hCG.<xref rid="rmb212008-bib-0002" ref-type="ref">2</xref>, <xref rid="rmb212008-bib-0006" ref-type="ref">6</xref>
</p><p>Furthermore, u&#x02010;hCG has a number of disadvantages, compared with r&#x02010;hCG, including batch&#x02010;to&#x02010;batch inconsistency, which has been observed to affect the treatment response and the potential for adverse immunologic reactions that are caused by the presence of non&#x02010;hCG proteins.<xref rid="rmb212008-bib-0006" ref-type="ref">6</xref>, <xref rid="rmb212008-bib-0007" ref-type="ref">7</xref>, <xref rid="rmb212008-bib-0008" ref-type="ref">8</xref>, <xref rid="rmb212008-bib-0009" ref-type="ref">9</xref> Outside of Japan, r&#x02010;hCG is, therefore, widely used for the induction of final follicular maturation and early luteinization in women who are undergoing ovulation induction, whereas in Japan u&#x02010;hCG is still predominantly used.</p><p>A phase III trial was conducted to investigate whether a single 250&#x000a0;&#x003bc;g s.c. dose of r&#x02010;hCG was non&#x02010;inferior to a single 5000&#x000a0;IU i.m. dose of u&#x02010;hCG for inducing ovulation in Japanese women who had been diagnosed with anovulation or oligo&#x02010;ovulation secondary to hypothalamic&#x02013;pituitary dysfunction or polycystic ovary syndrome (PCOS) and who were undergoing ovulation induction with recombinant&#x02010;human follicle&#x02010;stimulating hormone (r&#x02010;hFSH).</p></sec><sec id="rmb212008-sec-0006"><label>2</label><title>Materials and Methods</title><p>This was an open&#x02010;label, parallel&#x02010;group, randomized, multicenter, phase III trial (ClinicalTrials.gov. identifier: NCT01653743) in Japanese women who were undergoing ovulation induction with r&#x02010;hFSH. The study was performed in accordance with the ethical principles that have their origin in the Declaration of Helsinki, the International Conference on Harmonisation&#x02013;Good Clinical Practice guidelines, and all applicable regulatory requirements, with all the participants providing written informed consent prior to entry into the trial.</p><sec id="rmb212008-sec-0007"><label>2.1</label><title>Study participants</title><p>Healthy premenopausal Japanese women (aged 20&#x02010;39&#x000a0;years, inclusive) who wished to conceive, had a body mass index (BMI) of 17.0&#x02010;29.0&#x000a0;kg/m<sup>2</sup> (inclusive), and who were diagnosed with anovulation or oligo&#x02010;ovulation secondary to hypothalamic&#x02013;pituitary dysfunction (Grade 1 amenorrhea, oligomenorrhea, or anovulatory cycles) or PCOS were included if they met the following criteria: spontaneous menstruation (at least twice per year) or a positive response to progestin, as shown by menstruation; no known defect of the fallopian tubes that precluded ovulation induction; a normal uterine cavity on screening transvaginal ultrasound; a male partner with a normal semen analysis, as defined by World Health Organization standards, within 12&#x000a0;months prior to informed consent; and normal cervical smear results within 12&#x000a0;months prior to informed consent.</p><p>The exclusion criteria included infertility due to causes other than hypothalamic&#x02013;pituitary dysfunction or PCOS, a history of severe ovarian hyperstimulation syndrome (OHSS; classified according to the Japan Reproductive/Endocrine Working Group guidelines<xref rid="rmb212008-bib-0010" ref-type="ref">10</xref>), active thromboembolic disorders, the presence of, or suspected, gonadotropin&#x02010; or estrogen&#x02010;dependent malignancy, a history of allergic reaction or hypersensitivity to hCG&#x02010; or gonadotropin&#x02010;containing product(s) and/or their excipients, or a contraindication to pregnancy.</p></sec><sec id="rmb212008-sec-0008"><label>2.2</label><title>Study treatments and interventions</title><p>Women were enrolled at 15 centers in Japan and the trial was conducted between September 2012 and December 2014. The study design is shown in Figure&#x000a0;<xref rid="rmb212008-fig-0001" ref-type="fig">1</xref>. Women underwent ovulation induction therapy with single, daily injections of r&#x02010;hFSH (follitropin alfa; Merck KGaA, Darmstadt, Germany) according to a low&#x02010;dose, step&#x02010;up protocol for a maximum of 28&#x000a0;days, unless a rise in estradiol levels was recorded suggesting imminent follicular maturation. The starting dose of r&#x02010;hFSH was 75&#x000a0;IU s.c. per day, unless there was an indication of increased risk of OHSS or in cases in which a starting dose of &#x0003c;75&#x000a0;IU was recommended by the principal investigator. Dose increment changes of 37.5&#x000a0;IU every 7&#x000a0;days were permitted based on the ovarian response.</p><fig fig-type="Figure" xml:lang="en" id="rmb212008-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Study design. <styled-content style="fixed-case">hCG</styled-content>, human chorionic gonadotropin; Max., maximum; r&#x02010;<styled-content style="fixed-case">hFSH</styled-content>, recombinant&#x02010;human follicle&#x02010;stimulating hormone</p></caption><graphic id="nlm-graphic-1" xlink:href="RMB2-16-45-g001"/></fig><p>After stimulation with r&#x02010;hFSH was completed, patients were randomized (2:1) to receive either a single 250&#x000a0;&#x003bc;g s.c. dose of r&#x02010;hCG (Merck KGaA, Darmstadt, Germany) or a single 5000&#x000a0;IU i.m. dose of u&#x02010;hCG (Mochida Pharmaceutical Company, Ltd, Tokyo, Japan) once all of the following criteria were met: the mean diameter of the dominant follicle was &#x02265;18&#x000a0;mm; there were no more than three follicles with a mean diameter &#x02265;16&#x000a0;mm; and the serum estradiol level was within an acceptable range for the number of follicles present and was &#x02264;2000&#x000a0;pg/mL.</p><p>Women were randomized according to a predefined computer&#x02010;generated list in random permuted blocks that were stratified by site. Randomization was coordinated centrally via an interactive Voice and Web response system. Following hCG administration, fertilization was attempted through either intercourse within 48&#x000a0;hours of hCG administration or by intrauterine insemination, depending on the participant's preference. Intrauterine insemination was performed according to the normal procedures of the trial site. Luteal phase support was not provided during the trial.</p></sec><sec id="rmb212008-sec-0009"><label>2.3</label><title>Study objectives and end points</title><p>The primary objective of this study was to determine whether a single 250&#x000a0;&#x003bc;g s.c. dose of r&#x02010;hCG was non&#x02010;inferior to a single 5000&#x000a0;IU i.m. dose of u&#x02010;hCG for ovulation induction in Japanese women who had been diagnosed with anovulation or oligo&#x02010;ovulation secondary to hypothalamic&#x02013;pituitary dysfunction or PCOS and who were undergoing ovulation induction with r&#x02010;hFSH. The non&#x02010;inferiority margin was &#x02212;20%.</p><p>The primary efficacy end point was the ovulation rate, where ovulation was defined as a mid&#x02010;luteal serum progesterone level &#x02265;5&#x000a0;ng/mL, in all the participants who received hCG and had a serum progesterone level &#x0003c;5&#x000a0;ng/mL prior to hCG administration. The higher of the values taken on the visit on either days 5&#x02010;7 or days 8&#x02010;10 post&#x02010;hCG administration was taken as the final value for this determination. If clinical pregnancy was achieved, this was counted as successful ovulation, regardless of the mid&#x02010;luteal serum progesterone levels.</p><p>The secondary efficacy end points included the ovulation rate, where ovulation was defined as a mid&#x02010;luteal serum progesterone level &#x02265;9.4&#x000a0;ng/mL. Other secondary efficacy end points were mid&#x02010;luteal endometrial thickness and biochemical and clinical pregnancy rates. Biochemical pregnancy was defined as any miscarriage without evidence of a fetal sac on transvaginal ultrasound on the day 35&#x02010;42 post&#x02010;hCG visit, but with a positive serum &#x003b2;&#x02010;hCG pregnancy test (&#x003b2;&#x02010;hCG&#x0003e;10&#x000a0;IU/L) on the day 15&#x02010;20 post&#x02010;hCG administration visit. Clinical pregnancy was defined as the presence of a fetal sac on transvaginal ultrasound on the day 35&#x02010;42 post&#x02010;hCG administration visit.</p><p>Safety and tolerability, including the incidence and severity of AEs, incidence of OHSS, and local tolerability were also investigated. AEs were classified by their severity and causal relationship to the study treatment. AEs with an onset date occurring on or after hCG use were classed as &#x0201c;treatment&#x02010;emergent AEs&#x0201d; (TEAEs).</p></sec><sec id="rmb212008-sec-0010"><label>2.4</label><title>Statistical analysis</title><p>The ovulation rate following a single 5000&#x000a0;IU dose of u&#x02010;hCG as part of an ovulation induction cycle using r&#x02010;hFSH in a low&#x02010;dose, step&#x02010;up protocol was assumed to be 95%, based on observations from two Japanese trials of r&#x02010;hFSH for ovulation induction.<xref rid="rmb212008-bib-0011" ref-type="ref">11</xref> An ovulation rate of 95% also was observed in a global phase III trial that investigated a single 250&#x000a0;&#x003bc;g dose of r&#x02010;hCG as part of an ovulation induction cycle using r&#x02010;hFSH with a similar low&#x02010;dose, step&#x02010;up protocol.<xref rid="rmb212008-bib-0002" ref-type="ref">2</xref>
</p><p>Assuming that the ovulation rate would be 95% in both arms, 72 evaluable participants (48 treated with r&#x02010;hCG and 24 with u&#x02010;hCG) were required to demonstrate that the lower limit of the two&#x02010;sided 95% CI of the difference in the ovulation rate (r&#x02010;hCG minus u&#x02010;hCG) was above the non&#x02010;inferiority margin of &#x02212;20%, with at least 90% power. Allowing for a 15% cycle cancelation rate (based on the data from the trials that were used in the previous calculation<xref rid="rmb212008-bib-0011" ref-type="ref">11</xref>), a total of 87 participants needed to be enrolled in order that 72 might be evaluable.</p><p>The primary efficacy end point was investigated in the modified intention&#x02010;to&#x02010;treat (ITT) population, which included all the participants who were randomized to receive either r&#x02010;hCG or u&#x02010;hCG and who completed the primary efficacy assessment. The exact two&#x02010;sided 95% CI of the difference (Chang and Zhang method<xref rid="rmb212008-bib-0012" ref-type="ref">12</xref>) in ovulation rates was calculated and if the lower bound of the 95% CI was above &#x02212;20% then non&#x02010;inferiority was assumed. The secondary efficacy end points were also investigated in the modified ITT population and were reported as percentages with corresponding CIs. The safety analysis was conducted using the safety population, which included all participants who received either r&#x02010;hCG or u&#x02010;hCG.</p></sec></sec><sec id="rmb212008-sec-0011"><label>3</label><title>Results</title><p>A total of 189 women were screened for inclusion in the trial, of whom 125 were enrolled (Figure&#x000a0;<xref rid="rmb212008-fig-0002" ref-type="fig">2</xref>). Of these women, 124 started controlled ovarian stimulation with r&#x02010;hFSH and one woman discontinued prior to ovulation stimulation because of a spontaneous pregnancy. Forty&#x02010;three women discontinued during controlled ovarian stimulation, with the main reason for discontinuation being the risk of OHSS (n=30). Following controlled ovarian stimulation, 81 women were randomized to receive either r&#x02010;hCG (n=54) or u&#x02010;hCG (n=27) to trigger ovulation, and this represented both the modified ITT and safety populations. Subsequent to ovulation triggering, four women discontinued in the r&#x02010;hCG arm (due to inadequate compliance with trial medication [n=1], withdrawal of consent [n=1], the investigator's judgment [n=1], and the use of prohibited drugs [n=1]) and did not complete the trial.</p><fig fig-type="Figure" xml:lang="en" id="rmb212008-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Subject disposition. <styled-content style="fixed-case">hCG</styled-content>, human chorionic gonadotropin; <styled-content style="fixed-case">OHSS</styled-content>, ovarian hyperstimulation syndrome; r&#x02010;<styled-content style="fixed-case">hCG</styled-content>, recombinant&#x02010;human chorionic gonadotropin; r&#x02010;<styled-content style="fixed-case">hFSH</styled-content>, recombinant&#x02010;human follicle&#x02010;stimulating hormone; u&#x02010;<styled-content style="fixed-case">hCG</styled-content>, urine&#x02010;derived human chorionic gonadotropin</p></caption><graphic id="nlm-graphic-3" xlink:href="RMB2-16-45-g002"/></fig><sec id="rmb212008-sec-0012"><label>3.1</label><title>Baseline characteristics and demographics</title><p>Demographics, baseline characteristics, and infertility history were comparable between the two treatment groups (Table&#x000a0;<xref rid="rmb212008-tbl-0001" ref-type="table-wrap">1</xref>). The median age was 31.5&#x000a0;years, the median weight was 52.8&#x000a0;kg, and the median BMI was 20.8&#x000a0;kg/m<sup>2</sup>. The majority of the women had primary infertility, with all the participants having female infertility only. The main cause of female infertility was ovulatory dysfunction, mostly as a result of oligo&#x02010;ovulation. The median duration of infertility was longer in the group that received r&#x02010;hCG, compared with the group that received u&#x02010;hCG (2.0&#x000a0;years and 1.0&#x000a0;year, respectively).</p><table-wrap id="rmb212008-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics and demographics (modified intention&#x02010;to&#x02010;treat population)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">r&#x02010;hCG (n=54)</th><th align="left" valign="top" rowspan="1" colspan="1">u&#x02010;hCG (n=27)</th><th align="left" valign="top" rowspan="1" colspan="1">Overall (n=81)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years), median</td><td align="left" rowspan="1" colspan="1">33.30</td><td align="left" rowspan="1" colspan="1">30.00</td><td align="left" rowspan="1" colspan="1">31.50</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight (kg), median</td><td align="left" rowspan="1" colspan="1">51.55</td><td align="left" rowspan="1" colspan="1">54.50</td><td align="left" rowspan="1" colspan="1">52.80</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>), median</td><td align="left" rowspan="1" colspan="1">20.60</td><td align="left" rowspan="1" colspan="1">21.00</td><td align="left" rowspan="1" colspan="1">20.80</td></tr><tr><td align="left" colspan="4" rowspan="1">Infertility, N (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Primary</td><td align="left" rowspan="1" colspan="1">38 (70.4)</td><td align="left" rowspan="1" colspan="1">20 (74.1)</td><td align="left" rowspan="1" colspan="1">58 (71.6)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Secondary</td><td align="left" rowspan="1" colspan="1">16 (29.6)</td><td align="left" rowspan="1" colspan="1">7 (25.9)</td><td align="left" rowspan="1" colspan="1">23 (28.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration of infertility (years), median</td><td align="left" rowspan="1" colspan="1">2.0</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">2.0</td></tr><tr><td align="left" colspan="4" rowspan="1">Type of infertility, N (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Female infertility only</td><td align="left" rowspan="1" colspan="1">54 (100.0)</td><td align="left" rowspan="1" colspan="1">27 (100.0)</td><td align="left" rowspan="1" colspan="1">81 (100.0)</td></tr><tr><td align="left" colspan="4" rowspan="1">Cause(s) of female infertility, N (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Endometriosis</td><td align="left" rowspan="1" colspan="1">1 (1.9)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">1 (1.2)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Ovulatory dysfunction</td><td align="left" rowspan="1" colspan="1">54 (100.0)</td><td align="left" rowspan="1" colspan="1">27 (100.0)</td><td align="left" rowspan="1" colspan="1">81 (100.0)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Anovulation</td><td align="left" rowspan="1" colspan="1">5 (9.3)</td><td align="left" rowspan="1" colspan="1">2 (7.4)</td><td align="left" rowspan="1" colspan="1">7 (8.6)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Oligo&#x02010;ovulation</td><td align="left" rowspan="1" colspan="1">49 (90.7)</td><td align="left" rowspan="1" colspan="1">25 (92.6)</td><td align="left" rowspan="1" colspan="1">74 (91.4)</td></tr><tr><td align="left" colspan="4" rowspan="1">Causes of ovulatory dysfunction, N (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Grade 1 amenorrhea</td><td align="left" rowspan="1" colspan="1">7 (13.0)</td><td align="left" rowspan="1" colspan="1">5 (18.5)</td><td align="left" rowspan="1" colspan="1">12 (14.8)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Oligomenorrhea</td><td align="left" rowspan="1" colspan="1">34 (63.0)</td><td align="left" rowspan="1" colspan="1">14 (51.9)</td><td align="left" rowspan="1" colspan="1">48 (59.3)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Polycystic ovary syndrome</td><td align="left" rowspan="1" colspan="1">13 (24.1)</td><td align="left" rowspan="1" colspan="1">8 (29.6)</td><td align="left" rowspan="1" colspan="1">21 (25.9)</td></tr><tr><td align="left" colspan="4" rowspan="1">Type of menstruation, N (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Oligo&#x02010;amenorrhea (&#x0003c;6 periods/year)</td><td align="left" rowspan="1" colspan="1">17 (31.5)</td><td align="left" rowspan="1" colspan="1">13 (48.1)</td><td align="left" rowspan="1" colspan="1">30 (37.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Oligo&#x02010;amenorrhea (&#x02265;6 periods/year)</td><td align="left" rowspan="1" colspan="1">33 (61.1)</td><td align="left" rowspan="1" colspan="1">12 (44.4)</td><td align="left" rowspan="1" colspan="1">45 (55.6)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Secondary amenorrhea</td><td align="left" rowspan="1" colspan="1">4 (7.4)</td><td align="left" rowspan="1" colspan="1">1 (3.7)</td><td align="left" rowspan="1" colspan="1">5 (6.2)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Menstrual irregularity</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">1 (3.7)</td><td align="left" rowspan="1" colspan="1">1 (1.2)</td></tr></tbody></table><table-wrap-foot><fn id="rmb212008-note-0003"><p>BMI, body mass index; r&#x02010;hCG, recombinant&#x02010;human chorionic gonadotropin; u&#x02010;hCG, urine&#x02010;derived human chorionic gonadotropin.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="rmb212008-sec-0013"><label>3.2</label><title>Efficacy evaluation</title><p>For the primary efficacy evaluation, ovulation, defined as a mid&#x02010;luteal progesterone level &#x02265;5&#x000a0;ng/mL, was reported in all the participants in the modified ITT population (Table&#x000a0;<xref rid="rmb212008-tbl-0002" ref-type="table-wrap">2</xref>) and the lower limit of the two&#x02010;sided 95% CI of the difference between ovulation rates was &#x02212;7.8%, which was above the non&#x02010;inferiority margin of &#x02212;20%. Therefore, treatment with r&#x02010;hCG was non&#x02010;inferior to u&#x02010;hCG for ovulation induction. Furthermore, for the secondary efficacy evaluation, ovulation, defined as mid&#x02010;luteal progesterone &#x02265;9.4&#x000a0;ng/mL, was reported in 52 (96.3%) women who received r&#x02010;hCG and 24 (88.9%) women who received u&#x02010;hCG (Table&#x000a0;<xref rid="rmb212008-tbl-0002" ref-type="table-wrap">2</xref>). The lower limit of the two&#x02010;sided 95% CI of the difference between ovulation rates was &#x02212;5.2%, which was above the non&#x02010;inferiority margin of &#x02212;20%, also demonstrating non&#x02010;inferiority for this outcome.</p><table-wrap id="rmb212008-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Efficacy end points (modified intention&#x02010;to&#x02010;treat population)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">r&#x02010;hCG (n=54)</th><th align="left" valign="top" rowspan="1" colspan="1">u&#x02010;hCG (n=27)</th></tr></thead><tbody><tr><td align="left" colspan="3" rowspan="1">Primary endpoint</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Ovulation rate, defined as a mid&#x02010;luteal progesterone level &#x02265;5&#x000a0;ng/mL</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" colspan="3" rowspan="1">Participants with a serum progesterone level, N (%)</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">&#x0003c;5&#x000a0;ng/mL on day 0 post&#x02010;hCG visit</td><td align="left" rowspan="1" colspan="1">54 (100.0)</td><td align="left" rowspan="1" colspan="1">27 (100.0)</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">&#x02265;5&#x000a0;ng/mL on day 5&#x02010;7 post&#x02010;hCG visit</td><td align="left" rowspan="1" colspan="1">52 (96.3)</td><td align="left" rowspan="1" colspan="1">26 (96.3)</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">&#x02265;5&#x000a0;ng/mL on day 8&#x02010;10 post&#x02010;hCG visit</td><td align="left" rowspan="1" colspan="1">48 (88.9)</td><td align="left" rowspan="1" colspan="1">25 (92.6)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Participants with a mid&#x02010;luteal serum progesterone level &#x02265;5&#x000a0;ng/mL, N (%)</td><td align="left" rowspan="1" colspan="1">54 (100.0)</td><td align="left" rowspan="1" colspan="1">27 (100.0)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Participants with successful ovulation, N (%)</td><td align="left" rowspan="1" colspan="1">54 (100.0)</td><td align="left" rowspan="1" colspan="1">27 (100.0)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Difference in the ovulation rate, % (95% CI)</td><td align="left" colspan="2" rowspan="1">0.0 (&#x02212;7.8&#x02010;12.8)</td></tr><tr><td align="left" colspan="3" rowspan="1">Secondary endpoints</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Ovulation rate, defined as a mid&#x02010;luteal progesterone level &#x02265;9.4&#x000a0;ng/mL</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Participants with a mid&#x02010;luteal serum progesterone level &#x02265;9.4&#x000a0;ng/mL, N (%)</td><td align="left" rowspan="1" colspan="1">51 (94.4)</td><td align="left" rowspan="1" colspan="1">24 (88.9)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Ovulation rate defined by a progesterone level &#x02265;9.4&#x000a0;ng/mL or clinical pregnancy, N (%)</td><td align="left" rowspan="1" colspan="1">52 (96.3)</td><td align="left" rowspan="1" colspan="1">24 (88.9)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Difference in the ovulation rate, % (95% CI)</td><td align="left" colspan="2" rowspan="1">7.4 (&#x02013;5.2&#x02010;25.6)</td></tr><tr><td align="left" style="padding-left:10%" colspan="3" rowspan="1">Mid&#x02010;luteal endometrial thickness</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Median endometrial thickness, mm</td><td align="left" rowspan="1" colspan="1">11.0</td><td align="left" rowspan="1" colspan="1">12.0</td></tr><tr><td align="left" style="padding-left:10%" colspan="3" rowspan="1">Biochemical and clinical pregnancy rates</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Positive &#x003b2;&#x02010;hCG pregnancy test,<xref ref-type="fn" rid="rmb212008-note-0004">a</xref> N (%)</td><td align="left" rowspan="1" colspan="1">19 (35.2)</td><td align="left" rowspan="1" colspan="1">10 (37.0)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Biochemical pregnancy<xref ref-type="fn" rid="rmb212008-note-0004">b</xref> rate, % (95% CI)</td><td align="left" rowspan="1" colspan="1">3.7 (0.5&#x02010;12.7)</td><td align="left" rowspan="1" colspan="1">3.7 (0.1&#x02010;19.0)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Clinical pregnancy<xref ref-type="fn" rid="rmb212008-note-0004">c</xref> rate, % (95% CI)</td><td align="left" rowspan="1" colspan="1">29.6 (18.0&#x02010;43.6)</td><td align="left" rowspan="1" colspan="1">33.3 (16.5&#x02010;54.0)</td></tr></tbody></table><table-wrap-foot><fn id="rmb212008-note-0004"><p>CI, confidence interval; r&#x02010;hCG, recombinant&#x02010;human chorionic gonadotropin; u&#x02010;hCG, urine&#x02010;derived human chorionic gonadotropin.<sup>a</sup>&#x003b2;&#x02010;hCG (&#x003b2;&#x02010;human chorionic gonadotropin) pregnancy test was performed at the day 15&#x02010;20 post&#x02010;hCG administration visit (serum &#x003b2;&#x02010;hCG&#x0003e;10&#x000a0;IU/L).<sup>b</sup>Biochemical pregnancy was defined as any miscarriage without any evidence of a fetal sac on transvaginal ultrasound on the visit 35&#x02010;42&#x000a0;days following hCG administration despite a positive &#x003b2;&#x02010;hCG pregnancy test 15&#x02010;20&#x000a0;days post&#x02010;hCG. <sup>c</sup>Clinical pregnancy was defined as the presence of at least one fetal sac on transvaginal ultrasound at the visit 35&#x02010;42&#x000a0;days following hCG administration.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>The median mid&#x02010;luteal phase endometrial thickness 5&#x02010;7&#x000a0;days following hCG administration was comparable between the treatment groups: 11.0&#x000a0;mm and 12.0&#x000a0;mm in the r&#x02010;hCG and u&#x02010;hCG treatment groups, respectively. A similar proportion of women had a positive &#x003b2;&#x02010;hCG pregnancy test 15&#x02010;20&#x000a0;days following hCG administration: 35.2% of the women who had received r&#x02010;hCG and 37.0% of the women who had received u&#x02010;hCG. Biochemical pregnancy was reported in the same proportion of patients in both treatment arms (3.7% in both arms; Table&#x000a0;<xref rid="rmb212008-tbl-0002" ref-type="table-wrap">2</xref>). The clinical pregnancy rate was also comparable in both groups (29.6% and 33.3% with r&#x02010;hCG and u&#x02010;hCG, respectively; Table&#x000a0;<xref rid="rmb212008-tbl-0002" ref-type="table-wrap">2</xref>).</p></sec><sec id="rmb212008-sec-0014"><label>3.3</label><title>Safety evaluation</title><p>The incidence of AEs and hCG&#x02010;related TEAEs was higher in the group that received r&#x02010;hCG, compared with the group that received u&#x02010;hCG (Table&#x000a0;<xref rid="rmb212008-tbl-0003" ref-type="table-wrap">3</xref>). At least one AE was experienced pre&#x02010;hCG administration by 27.8% and 11.1% of the women who received r&#x02010;hCG and u&#x02010;hCG, respectively. At least one hCG&#x02010;related TEAE was experienced by 38.9% of the women who received r&#x02010;hCG and 29.6% of the women who received u&#x02010;hCG. The type and frequency of TEAEs did not represent any new safety concerns, compared with the known safety profile of r&#x02010;hCG.<xref rid="rmb212008-bib-0005" ref-type="ref">5</xref>
</p><table-wrap id="rmb212008-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Summary of adverse events (AEs) (safety population)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">r&#x02010;hCG (n=54)N (%)</th><th align="left" valign="top" rowspan="1" colspan="1">u&#x02010;hCG (n=27)N (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">At least one AE pre&#x02010;hCG administration</td><td align="left" rowspan="1" colspan="1">15 (27.8)</td><td align="left" rowspan="1" colspan="1">3 (11.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">At least one TEAE</td><td align="left" rowspan="1" colspan="1">33 (61.1)</td><td align="left" rowspan="1" colspan="1">11 (40.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">At least one hCG&#x02010;related TEAE</td><td align="left" rowspan="1" colspan="1">21 (38.9)</td><td align="left" rowspan="1" colspan="1">8 (29.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">At least one serious AE</td><td align="left" rowspan="1" colspan="1">1 (1.9)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">At least one serious hCG&#x02010;related TEAE</td><td align="left" rowspan="1" colspan="1">1 (1.9)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Death</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr></tbody></table><table-wrap-foot><fn id="rmb212008-note-0005"><p>hCG, human chorionic gonadotropin; r&#x02010;hCG, recombinant&#x02010;human chorionic gonadotropin; TEAE, treatment&#x02010;emergent adverse event; u&#x02010;hCG, urine&#x02010;derived human chorionic gonadotropin.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>The most commonly reported TEAEs were OHSS, ovarian cyst, and injection site erythema and pain. Mild, moderate, and severe OHSS were reported by 7.4%, 3.7%, and 3.7% of the patients who were treated with r&#x02010;hCG and 7.4%, 7.4%, and 0.0% of those who were treated with u&#x02010;hCG. In one participant from the r&#x02010;hCG group, OHSS was considered to be a serious TEAE in one participant who received r&#x02010;hCG. The incidence of ovarian cyst was identical with r&#x02010;hCG and u&#x02010;hCG, occurring in 11.1% of participants in both groups. Injection site erythema was reported by 9.3% and 7.4% of the women who received r&#x02010;hCG and u&#x02010;hCG, respectively, and injection site pain was reported by 3.7% and 11.1% of women, respectively. All the injection site AEs were mild in intensity.</p></sec></sec><sec id="rmb212008-sec-0015"><label>4</label><title>Discussion</title><p>This open&#x02010;label, randomized controlled trial, in 81 women who were undergoing controlled ovarian stimulation, demonstrated that r&#x02010;hCG was non&#x02010;inferior to u&#x02010;hCG for inducing ovulation in Japanese women who had been diagnosed with anovulation or oligo&#x02010;ovulation secondary to hypothalamic&#x02013;pituitary dysfunction or PCOS and who were undergoing ovulation induction with r&#x02010;hFSH. Similar proportions of women who received r&#x02010;hCG and u&#x02010;hCG had positive &#x003b2;&#x02010;hCG pregnancy tests and the mid&#x02010;luteal phase endometrial thickness was comparable in both groups. The clinical pregnancy rate was also similar in women who received r&#x02010;hCG or u&#x02010;hCG.</p><p>A higher proportion of women experienced TEAEs with r&#x02010;hCG, compared with those who received u&#x02010;hCG (38.9% vs 29.6%, respectively). This result is different from those that have been reported previously by trials comparing r&#x02010;hCG with u&#x02010;hCG, which report significantly fewer AEs with r&#x02010;hCG.<xref rid="rmb212008-bib-0002" ref-type="ref">2</xref>, <xref rid="rmb212008-bib-0004" ref-type="ref">4</xref>, <xref rid="rmb212008-bib-0005" ref-type="ref">5</xref>, <xref rid="rmb212008-bib-0006" ref-type="ref">6</xref>, <xref rid="rmb212008-bib-0013" ref-type="ref">13</xref>, <xref rid="rmb212008-bib-0014" ref-type="ref">14</xref> It should be noted that the incidence of AEs pre&#x02010;hCG administration was also higher in the group that received r&#x02010;hCG compared with the group that received u&#x02010;hCG. Furthermore, the overall incidence of OHSS that was observed in this study (14.8% in both arms) was higher than that reported in the literature or previous trials.<xref rid="rmb212008-bib-0002" ref-type="ref">2</xref>, <xref rid="rmb212008-bib-0006" ref-type="ref">6</xref>, <xref rid="rmb212008-bib-0014" ref-type="ref">14</xref> This higher incidence might be because most studies only report moderate and severe OHSS, rather than all OHSS, and if the incidence of mild OHSS is removed, the hCG&#x02010;related OHSS rates are comparable with other studies (moderate or severe OHSS: 7.4% in both the r&#x02010;hCG and the u&#x02010;hCG treatment groups).</p><p>Overall, the type and severity of AEs that were observed were as expected for women receiving fertility treatment.<xref rid="rmb212008-bib-0002" ref-type="ref">2</xref>, <xref rid="rmb212008-bib-0005" ref-type="ref">5</xref>, <xref rid="rmb212008-bib-0006" ref-type="ref">6</xref> These results highlight that r&#x02010;hCG for ovulation triggering is similarly effective and has a similar safety profile compared with u&#x02010;hCG in this population. Local tolerability was similar in both groups, except for pain, which was lower with r&#x02010;hCG compared with u&#x02010;hCG. This might potentially increase patient acceptability,<xref rid="rmb212008-bib-0013" ref-type="ref">13</xref> making home injection more suitable with r&#x02010;hCG.</p><p>A potential limitation of this study was its open&#x02010;label design; however, owing to the mechanism of action of hCG and the similarity of the results to those from global studies, it is unlikely that this would have affected the outcomes.<xref rid="rmb212008-bib-0002" ref-type="ref">2</xref>, <xref rid="rmb212008-bib-0005" ref-type="ref">5</xref>, <xref rid="rmb212008-bib-0006" ref-type="ref">6</xref> In addition, some causes of ovulatory dysfunction (eg, infertility due to causes other than hypothalamic&#x02013;pituitary dysfunction or PCOS) were listed in the exclusion criteria and therefore not the entire population of patients with ovulatory dysfunction is reflected in this trial.</p><p>In conclusion, this phase III study demonstrated that the efficacy of a single 250&#x000a0;&#x003bc;g s.c. dose of r&#x02010;hCG was non&#x02010;inferior to a single 5000&#x000a0;IU i.m. dose of u&#x02010;hCG in inducing ovulation in Japanese women who had been diagnosed with anovulation or oligo&#x02010;ovulation secondary to hypothalamic&#x02013;pituitary dysfunction or PCOS and who were undergoing ovulation induction with r&#x02010;hFSH. A 100% ovulation rate was observed with both r&#x02010;hCG and u&#x02010;hCG. Furthermore, r&#x02010;hCG demonstrated an expected safety profile in women receiving fertility treatment, with no new safety concerns identified.</p></sec><sec id="rmb212008-sec-0017"><title>Disclosure</title><p>
<italic>Conflicts of interest</italic>: Daniela Rogoff is a former employee of EMD Serono Research &#x00026; Development Institute, Inc., a business of Merck KGaA, Darmstadt, Germany. Shin Shimizu is an employee of Merck Serono Company, Ltd, an affiliate of Merck KGaA, Darmstadt, Germany. Hideyuki Ikenaga, Yudai Tanaka, Masahide Shiotani, and Osamu Ishihara declare that they have no relevant conflict of interest. <italic>Human rights statement and informed consent</italic>: All the procedures that were followed were in accordance with the ethical standards of the responsible committees on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and its later amendments. Informed consent was obtained from all the patients to be included in the study. <italic>Animal studies</italic>: This article does not contain any studies with animals performed by any of the authors.</p></sec></body><back><ack id="rmb212008-sec-0016"><title>Acknowledgements</title><p>The trial was sponsored by Merck KGaA, Darmstadt, Germany. The authors would like to thank the patients and their families, investigators, co&#x02010;investigators, and the study teams at each of the participating centers and at Merck KGaA, Darmstadt, Germany. The study investigators were: Yoshiaki Sato, Yoshiharu Morimoto, Aisaku Fukuda, Kohzo Aisaka, Koji Yoshida, Naoki Hayashi, Hirotsugu Oku, Yuji Abe, Atsushi Haruki, Motoharu Ishikawa, and Takeshi Kuramoto. Medical writing assistance was provided by Alexander Jones, inScience Communications, London, UK, and was funded by Merck KGaA, Darmstadt, Germany.</p></ack><ref-list content-type="cited-references" id="rmb212008-bibl-0001"><title>References</title><ref id="rmb212008-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="rmb212008-cit-0001">
<string-name>
<surname>Matorras</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Meabe</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Mendoza</surname>
<given-names>R</given-names>
</string-name>, et&#x000a0;al. <article-title>Human chorionic gonadotropin (hCG) plasma levels at oocyte retrieval and IVF outcomes</article-title>. <source>J Assist Reprod Genet</source>. <year>2012</year>;<volume>29</volume>:<fpage>1067</fpage>&#x02013;<lpage>1071</lpage>.<pub-id pub-id-type="pmid">22815004</pub-id></mixed-citation></ref><ref id="rmb212008-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="rmb212008-cit-0002">
<collab collab-type="authors">International Recombinant Human Chorionic Gonadotropin Study Group</collab>
. <article-title>Induction of ovulation in World Health Organization group II anovulatory women undergoing follicular stimulation with recombinant human follicle&#x02010;stimulating hormone: a comparison of recombinant human chorionic gonadotropin (rhCG) and urinary hCG</article-title>. <source>Fertil Steril</source>. <year>2001</year>;<volume>75</volume>:<fpage>1111</fpage>&#x02013;<lpage>1118</lpage>.<pub-id pub-id-type="pmid">11384635</pub-id></mixed-citation></ref><ref id="rmb212008-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="rmb212008-cit-0003">
<string-name>
<surname>Chang</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kenley</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Burns</surname>
<given-names>T</given-names>
</string-name>, et&#x000a0;al. <article-title>Recombinant human chorionic gonadotropin (rhCG) in assisted reproductive technology: results of a clinical trial comparing two doses of rhCG (Ovidrel) to urinary hCG (Profasi) for induction of final follicular maturation in in vitro fertilization&#x02013;embryo transfer</article-title>. <source>Fertil Steril</source>. <year>2001</year>;<volume>76</volume>:<fpage>67</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">11438321</pub-id></mixed-citation></ref><ref id="rmb212008-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="rmb212008-cit-0004">
<string-name>
<surname>Driscoll</surname>
<given-names>GL</given-names>
</string-name>, <string-name>
<surname>Tyler</surname>
<given-names>JPP</given-names>
</string-name>, <string-name>
<surname>Hangan</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Fisher</surname>
<given-names>PR</given-names>
</string-name>, <string-name>
<surname>Birdsall</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Knight</surname>
<given-names>DC</given-names>
</string-name>. <article-title>A prospective, randomized, controlled, double&#x02010;blind, double&#x02010;dummy comparison of recombinant and urinary HCG for inducing oocyte maturation and follicular luteinization in ovarian stimulation</article-title>. <source>Hum Reprod</source>. <year>2000</year>;<volume>15</volume>:<fpage>1305</fpage>&#x02013;<lpage>1310</lpage>.<pub-id pub-id-type="pmid">10831560</pub-id></mixed-citation></ref><ref id="rmb212008-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="rmb212008-cit-0005">
<string-name>
<surname>Youssef</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Al&#x02010;Inany</surname>
<given-names>HG</given-names>
</string-name>, <string-name>
<surname>Aboulghar</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mansour</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Abou&#x02010;Setta</surname>
<given-names>AM</given-names>
</string-name>. <article-title>Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2011</year>;<volume>2011</volume>:<fpage>CD003719</fpage>.</mixed-citation></ref><ref id="rmb212008-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="rmb212008-cit-0006">
<collab collab-type="authors">The European Recombinant Human Chorionic Gonadotrophin Study Group</collab>
. <article-title>Induction of final follicular maturation and early luteinization in women undergoing ovulation induction for assisted reproduction treatment &#x02013; recombinant HCG versus urinary HCG. The European Recombinant Human Chorionic Gonadotrophin Study Group</article-title>. <source>Hum Reprod</source>. <year>2000</year>;<volume>15</volume>:<fpage>1446</fpage>&#x02013;<lpage>1451</lpage>.<pub-id pub-id-type="pmid">10875887</pub-id></mixed-citation></ref><ref id="rmb212008-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="rmb212008-cit-0007">
<string-name>
<surname>Zegers&#x02010;Hochschild</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Fernandez</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Mackenna</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Fabres</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Altieri</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Lopez</surname>
<given-names>T</given-names>
</string-name>. <article-title>The empty follicle syndrome: a pharmaceutical industry syndrome</article-title>. <source>Hum Reprod</source>. <year>1995</year>;<volume>10</volume>:<fpage>2262</fpage>&#x02013;<lpage>2265</lpage>.<pub-id pub-id-type="pmid">8530648</pub-id></mixed-citation></ref><ref id="rmb212008-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="rmb212008-cit-0008">
<string-name>
<surname>Al&#x02010;Inany</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Aboulghar</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Mansour</surname>
<given-names>RT</given-names>
</string-name>, <string-name>
<surname>Proctor</surname>
<given-names>M</given-names>
</string-name>. <article-title>Recombinant versus urinary gonadotrophins for triggering ovulation in assisted conception</article-title>. <source>Hum Reprod</source>. <year>2005</year>;<volume>20</volume>:<fpage>2061</fpage>&#x02013;<lpage>2073</lpage>.<pub-id pub-id-type="pmid">16024539</pub-id></mixed-citation></ref><ref id="rmb212008-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="rmb212008-cit-0009">
<string-name>
<surname>Morse</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Lustbader</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Harrington</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Canfield</surname>
<given-names>RE</given-names>
</string-name>. <article-title>Heterogeneity of proteins in commercial preparations of human chorionic gonadotropin (hCG) demonstrated by Western blotting</article-title>. <source>Am J Reprod Immunol Microbiol</source>. <year>1988</year>;<volume>17</volume>:<fpage>134</fpage>&#x02013;<lpage>140</lpage>.<pub-id pub-id-type="pmid">3202237</pub-id></mixed-citation></ref><ref id="rmb212008-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="rmb212008-cit-0010">
<collab collab-type="authors">Reproductive/Endocrine Working Group</collab>
. <article-title>Classification of OHSS severity</article-title>. <source>Acta Obstet Gynecol Jpn</source>. <year>2009</year>;<volume>61</volume>:<fpage>1138</fpage>&#x02013;<lpage>1145</lpage>.</mixed-citation></ref><ref id="rmb212008-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="rmb212008-cit-0011">
<string-name>
<surname>Taketani</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kelly</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Yoshimura</surname>
<given-names>Y</given-names>
</string-name>, et&#x000a0;al. <article-title>Recombinant follicle&#x02010;stimulating hormone (follitropin alfa) versus purified urinary follicle&#x02010;stimulating hormone in a low&#x02010;dose step&#x02010;up regimen to induce ovulation in Japanese women with anti&#x02010;estrogen&#x02010;ineffective oligo&#x02010; or anovulatory infertility: results of a single&#x02010;blind Phase III study</article-title>. <source>Reprod Med Biol</source>. <year>2010</year>;<volume>9</volume>:<fpage>99</fpage>&#x02013;<lpage>106</lpage>.</mixed-citation></ref><ref id="rmb212008-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="rmb212008-cit-0012">
<string-name>
<surname>Chan</surname>
<given-names>IS</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</string-name>. <article-title>Test&#x02010;based exact confidence intervals for the difference of two binomial proportions</article-title>. <source>Biometrics</source>. <year>1999</year>;<volume>55</volume>:<fpage>1202</fpage>&#x02013;<lpage>1209</lpage>.<pub-id pub-id-type="pmid">11315068</pub-id></mixed-citation></ref><ref id="rmb212008-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="rmb212008-cit-0013">
<string-name>
<surname>Abdelmassih</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Oliveira</surname>
<given-names>FG</given-names>
</string-name>, <string-name>
<surname>Goncalves</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Varella</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Diamond</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Abdelmassih</surname>
<given-names>R</given-names>
</string-name>. <article-title>A prospective, randomized and blinded comparison between 10,000&#x000a0;IU urinary and 250&#x000a0;&#x003bc;g recombinant human chorionic gonadotropin for oocyte maturation in in vitro fertilization cycles</article-title>. <source>J Assist Reprod Genet</source>. <year>2005</year>;<volume>22</volume>:<fpage>149</fpage>&#x02013;<lpage>153</lpage>.<pub-id pub-id-type="pmid">16021858</pub-id></mixed-citation></ref><ref id="rmb212008-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="rmb212008-cit-0014">
<string-name>
<surname>Madani</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Mohammadi Yeganeh</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ezabadi</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Hasani</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Chehrazi</surname>
<given-names>M</given-names>
</string-name>. <article-title>Comparing the efficacy of urinary and recombinant hCG on oocyte/follicle ratio to trigger ovulation in women undergoing intracytoplasmic sperm injection cycles: a randomized controlled trial</article-title>. <source>J Assist Reprod Genet</source>. <year>2013</year>;<volume>30</volume>:<fpage>239</fpage>&#x02013;<lpage>245</lpage>.<pub-id pub-id-type="pmid">23274511</pub-id></mixed-citation></ref></ref-list></back></article>